anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Disease resistance is often associated with compromised plant growth and yield due to defense-growth tradeoffs. However, key components and mechanisms underlying the defense-growth tradeoffs are rarely explored in maize. In this study, we find that ZmSKI3, a putative subunit of the SUPERKILLER (SKI) complex that mediates the 3'-5' degradation of RNA, regulates both plant development and disease resistance in maize. The Zmski3 mutants showed retarded plant growth and constitutively activated defense responses, while the ZmSKI3 overexpression lines are more susceptible to Curvularia lunata and Bipolaris maydis. Consistently, the expression of defense-related genes was generally up-regulated, while expressions of growth-related genes were mostly down-regulated in leaves of the Zmski3-1 mutant compared to that of wild type. In addition, 223 differentially expressed genes that are up-regulated in Zmski3-1 mutant but down-regulated in the ZmSKI3 overexpression line are identified as potential target genes of ZmSKI3. Moreover, small interfering RNAs targeting the transcripts of the defense- and growth-related genes are differentially accumulated, likely to combat the increase of defense-related transcripts but decrease of growth-related transcripts in Zmski3-1 mutant. Taken together, our study indicates that plant growth and immunity could be regulated by both ZmSKI3-mediated RNA decay and post-transcriptional gene silencing in maize.
Chronic HCV patients, non complicated will be treated by Herbal tablets only . 500 mg twice tablets every 6 hours daily for 6 months.
Commercially available dextrose 5% injection with a UK marketing authorisation at equivalent dose volume will be used for the placebo formulation. Placebo and Active doses appearing identical at point of issue and administration.
Objective: Language dysfunction is one of the most common cognitive impairments in amyotrophic lateral sclerosis (ALS). Although discourse capacities are essential for daily functioning, verbal expressive language has not been widely investigated in ALS. The existing research available suggests that discourse impairments are prevalent. This study investigates verbal expressive language in people living with ALS (plwALS) in contrast to healthy controls (HC).Methods: 64 plwALS and 49 age, gender and education-matched healthy controls were ask to describe the Cookie Theft Picture Task. The recordings were analyzed for discourse productivity, discourse content, syntactic complexity, speech fluency and verb processing. We applied the Bayesian hypothesis-testing framework, incorporating the effects of dysarthria, cognitive impairment status (CIS), and premorbid crystalline verbal IQ.Results: Compared to HC, plwALS only showed a single impairment: speech dysfluency. Discourse productivity, discourse content, syntactic complexity and verb processing were not impaired. Cognition and dysarthria exceeded the influence of verbal IQ for total words spoken and content density. Cognition alone seemed to explain dysfluency. Body-agent verbs were produced at even higher rates than other verb types. For the remaining outcomes, verbal IQ was the most decisive factor.Conclusions: In contrast to existing research, our data demonstrates no discernible impairment in verbal expressive language in ALS. What our findings show to be decisive is accounting for the influence of dysarthria, cognitive impairment status, and verbal IQ as variables on spontaneous verbal expressive language. Minor impairments in verbal expressive language appear to be influenced to a greater degree by executive dysfunctioning and dysarthria than by language impairment.
People who have suffered cancer often do not find an adequate therapeutic response for the sequelae derived from its treatments. The objectives of this study are: 1) To design and implement the PaiNEd system for the evaluation and treatment based on Pain Neuroscience Education (PNE) in cancer survivors with sequelae derived from medical treatments; 2) Study the effectiveness of the PaiNEd system integrated in a multimodal physical recovery program compared to traditional biomedical information. In this regard, there is a shortage of proposals for certain subgroups of patients who demand special attention. This project aims to first carry out the design and implementation of an e-health system for the evaluation and treatment of pain. A randomized controlled experimental study will be carried out in which 72 breast cancer survivors will be recruited and randomly assigned to the three study groups: a) physical recovery program + access to the PaiNEd system; b) physical recovery program + traditional biomedical recommendations; c) control group. The evaluation will be carried out at baseline (at the beginning of the study), at 8 weeks (time of completion of the intervention) and at 6 months of follow-up of the patients.
PROBLEM TO BE SOLVED: To obtain a foaming or foamable composition by compounding a surfactant comprising a specific glucose derivative, a surfactant comprising a specific glycerol carboxylic acid ester, and an electrolyte. SOLUTION: This foaming or foamable composition comprises a surfactant comprising a glucose derivative of formula I (R is an alkyl; R1 is H, an alkyl; R2 is H, an acyl), a surfactant comprising a glycerol monocarboxylic acid of formula II or III (R3 is an acyl) or its monoester, and a cosmetically or pharmaceutically permissible electrolyte. The composition may further be compounded with an aqueous phase capable of containing a known soluble or dispersible substance and, if necessary, the same oily phase. The compound of formula I is preferably the compound of formula I wherein R is myristyl, palmityl, stearyl, etc.; R1 is H, methyl, ethyl, propyl, etc.; R2 is H, myristoryl, palmitoyl, etc. The composition is useful as a make-up cleansing cream, a post-foamable shaving gel, etc.
Presented herein are methods and compositions for an improved natural essential oil skincare formulation. In a preferred embodiment of the present invention, the formulation comprises at least CBG, CBD, CBN, hemp oil, hemp seed oil, and coconut oil. The formulation may consist of other natural components at varying concentrations, depending on the purpose of its use. Also disclosed are methods of using the disclosed formulation. referred method of use comprises identifying a condition to be treated and applying the composition disclosed herein to the skin to treat the condition. The methods and compositions disclosed herein may be used on humans or animals, for various topical uses.
PROBLEM TO BE SOLVED: To provide a process for increasing the viscosity of a siloxane fluid having low molecular weight by swelling the fluid with a silicone elastomer. SOLUTION: The silicone elastomer to be used in the present process is produced by crosslinking a siloxane containing ≡Si-H group and an unsaturated hydrocarbon such as an α,ω-diene in the presence of a siloxane fluid having low molecular weight. The siloxane containing ≡Si-H group is first made to partially react with a monoacrylate-functional polyether or a monomethacrylate- functional polyether and then crosslinked with an α,ω-diene in the presence of a siloxane fluid having low molecular weight. An elastomer having polyether group, i.e., a gel is formed by this process. The elastomer gel is swollen with the siloxane fluid having low molecular weight under a shearing force to obtain a homogeneous silicone paste. The silicone paste has excellent applicability in friction and exhibits unique rheological properties. The silicone paste is easily emulsifiable with water to form a stable homogeneous emulsion without using a surfactant generally used for sufficiently mixing an immiscible material.
PROBLEM TO BE SOLVED: To obtain a trichogen containing the combination of a specific substance having an odd carbon atom number chain with a natural substance extract and excellent in a hair growth-stimulating action. SOLUTION: This trichogen contains the following ingredients (A) and (B). (A) 0.01-20wt.% of a compound selected from fatty acids having odd carbon atom number chains, alcohols having odd carbon atom number chains and their derivatives. (B) 0.01-30wt.% of at least one kind of substance selected from the extract of Gentiana lutea, the extract of pine cones, the extract of royal jelly, the extract of Sasa albo-marginata, and the hydrolyzate solution of conchyolin. The ingredient A includes a monoglyceride of formula I (R1 is a linear organic group having an even carbon atom number chain) and a diglyceride of formula II (R2 , R3 are each a linear organic groups wherein one of the groups is an even carbon atom number linear organic group). The direct application of the trichogen to scalp exhibits a stronger trichogenous effect.
This is an open-label, multicenter, randomized controlled clinical trial. We plan to recruit 104 subjects and randomly assign them in a 2:1 ratio to either the experimental group receiving Anlotinib plus Benmelstobart plus Gemcitabine and Nab-Paclitaxel, or the control group receiving Gemcitabine and Nab-Paclitaxel as initial treatment. Each cycle of the aforementioned drugs will last three weeks, with tumor efficacy assessments conducted at the end of cycles 2, 4, 6, and 8. After 8 cycles of treatment, patients in the experimental group who achieve complete response (CR), partial response (PR), or stable disease (SD) will continue with maintenance therapy using Anlotinib plus Benmelstobart plus Gemcitabine. Similarly, after 8 cycles of treatment, patients in the control group who achieve CR, PR, or SD will continue with maintenance therapy using Gemcitabine monotherapy. Efficacy will be evaluated every 3 cycles (9 weeks) during the maintenance phase until disease progression or intolerability. This study aims to evaluate the efficacy and safety of the combination of Anlotinib and Benmelstobart with Gemcitabine and Nab-Paclitaxel in treating metastatic pancreatic cancer, providing a new treatment option for first-line therapy in patients with advanced metastatic pancreatic cancer.
Anal cancer incidence is increasing and although women compose more than half of all cases and those with HPV related lower genital tract dysplasia/malignancy have an even greater risk screening is currently not recommended. We therefore propose performing a prospective cohort study to determine the prevalence of anal dysplasia in women with high-grade lower genital tract dysplasia using high-resolution anoscopy HRA. This will then potentially lead to the development of a screening, diagnosis and treatment schema that can be implemented in all women with high-grade lower genital tract dysplasia. This study can potentially have a high impact on health delivery in women at high risk for anal cancer as this can transform the current treatment of anal cancer to a preventive screening program. This can later be implemented throughout Ontario and in all centers that treat women with cervical dysplasia.

The incidence of anal intraepithelial neoplasm (AIN also known as anal cancer) has increased in Ontario over the last 20 years. Two-thirds of the cases are found in women. The average time between diagnosis of anal cancer and previous cervical dysplasia or cancer is approximately 20 years. This study is giving the opportunity to detect and treat pre-invasive lesions and potentially prevent the development of anal cancer. Currently, no screening, diagnosis or treatment recommendation for anal dysplasia found in women with high-grade lower genital tract dysplasia.
In Cohort 1, doses of BPM31510 Oral Nanosuspension 4% will be administered two times per day before the morning and evening meals with no less than 8 and no more than 10 hours between doses. Immediately after administration, subjects will ingest 6 ounces of tap or bottled water. Solid food and drinks, other than water should be restricted to 2 hours before and 1 hour after dosing.
PROBLEM TO BE SOLVED: To obtain a new DNA composed of a DNA containing a base sequence coding for a growth factor for hepatocyte derived from human leukocyte and useful e.g. for producing a substance useful as a hepatocyte culturing agent, a hepato regeneration-accelerator, a clinical diagnostic agent and a treating agent for hepatic diseases, and for researches of hepatic function, etc. SOLUTION: This new DNA is composed of a base sequence coding for a growth factor for hepatocyte derived from human leukocyte. The DNA is useful e.g. for producing a polypeptide having growth activity on hepatocyte, which polypeptide is useful as a hepatocyte culturing agent, a hepato regeneration-accelerator, a clinical diagnostic agent and a treating agent for hepatic diseases, and for a basic research of hepatic function, researches of effects on hepatocyte of various kinds of hormones and agents and a research of the carcinogenesis of hepatic cancer, etc.  The DNA is obtained as follows: an mRNA is separated from human leukocytes; a cDNA library is produced according to a common method; and the resultant cDNA library derived from human leukocytes is screened using a probe consisting of the total or a part of the cDNA, which has already been isolated, for a growth factor for hepatocyte derived from human liver.
PURPOSE: Cervical hemivertebrae (C3-6) causing significant osseous torticollis, head tilt and facial asymmetry are rare and complicated. Cervical hemivertebrectomy (CHVE) by a posterior-only approach was never reported because it is highly risky and its efficacy remains controversial. This study is to evaluate the feasibility and preliminary clinical outcomes of posterior-only approach for CHVE and torticollis correction in young children.
METHODS: Four young children aged 5-9 years old with significant torticollis caused by cervical hemivertebrae underwent deformity correction consisting of cervical pedicle screw (CPS) placement with O-arm-based intraoperative navigation, CHVE using ultrasonic bone scalpel and short-segmental posterior instrumentation and fusion. Details of this novel technique were presented. The preliminary short-term clinical and radiographic outcomes were assessed.
RESULTS: On average, the operative time was 312.5 ± 49.9 min, and the surgical blood loss was 375.0 ± 150.0 ml. The structural cervical scoliosis was corrected from 31.5 ± 7.3° to 11.0 ± 4.1°, and the average correction rate was 64.9%. Head tilt was favorably corrected from 11.0 ± 4.2° to 3.5 ± 2.6°. The shoulder balance improved from 6.3 ± 1.3° to 1.5 ± 1.9°. One case with C6 CHVE had convex side radiating nerve root pain but no sign of muscle power weakness. Full recovery was achieved one month after surgery. No other complication occurred.
CONCLUSIONS: CHVE by a posterior-only approach was a feasible alternative option for the treatment of congenital cervical scoliosis. It could resect the CHV effectively and achieve satisfactory torticollis correction without additional anterior access surgery. Successful CPS placement in this child population was essentially important to enable reliable osteotomy closure and firm posterior instrumentation.
FIELD: medicine, gastroenterology. SUBSTANCE: in period of supposed exacerbation one should carry out course of certain therapy for 7-10 d. Type of patient's personality should be determined to prescribe either amitryptilin or nesepam. Patients with braking type of personality - amitryptilin, with excitable type - nosepam. The suggested method enables to prevent relapses and complications. EFFECT: higher efficiency of prophylaxis. 3 cl, 2 ex
Patients that do not wish to receive study treatment but agree to otherwise follow study protocol will also be enrolled in an observational cohort. They will receive the standard of care 3-5 days 1000mg IV methylprednisolone.
Children will be measured 5 times using a pulse oximeter. The measurements will be performed consecutively without any interval between them. The first measurement will be performed without using any gloves on the patient's finger, the second measurement will be performed using transparent gloves, the third measurement will be performed using white gloves, the fourth measurement will be performed using black gloves, and the fifth measurement will be performed using blue gloves.
An abdominal support tape will be added to the LPKT. In order to reduce the tension of the uterus ligaments, and to help perception of the normal elasticity of the target tissues, ligament technique will be used. The middle part of an I-shaped tape will be placed to the midpoint of the lower abdomen, and then will be progressed laterally and above with 50% tension.
He, Ben, Jiayue Feng, Yan Shu, Lichun Yang, Zepin He, Kanxiu Liao, Hui Zhuo, and Hui Li. Prevalence and risk factors of hyperuricemia among young and middle-aged Tibetan men living at ultrahigh altitudes: a cross-sectional study. High Alt Med Biol. 25:42-48, 2024. Background: Few studies have examined the prevalence or risk factors of hyperuricemia among populations living at ultrahigh altitudes. Here we examined the prevalence of hyperuricemia and factors associated with it among young and middle-aged Tibetan men living at ultrahigh altitudes. Methods: This cross-sectional study analyzed 672 Tibetan men 18-60 years old living on the Qinghai-Tibet Plateau (mean altitude 4,014 m) within the county of Litang in the Ganzi Tibetan autonomous prefecture of Sichuan Province, China. Demographic and clinical data were collected from self-administered questionnaires, physical examinations and laboratory tests. Participants whose blood uric acid (UA) contained >420 μmol/l were classified as having hyperuricemia. Results: Of the 672 men analyzed, 332 (49.4%) had hyperuricemia. Multivariate logistic regression showed risk of hyperuricemia to correlate positively with body mass index (per 1 U increase: odds ratio [OR] 1.172, 95% confidence interval [CI] 1.1066-1.243), triglycerides (OR 1.408, 95% CI 1.084-1.828), red blood cell count (OR 1.376, 95% CI 1.009-1.875), and creatinine level (per 1 U increase: OR 1.051, 95% CI 1.033-1.070). Conversely, risk of hyperuricemia correlated negatively with the presence of diabetes mellitus (OR 0.412, 95% CI 0.175-0.968). Subgroup analyses showed that prevalence of hyperuricemia was significantly higher among those with polycythemia than among those without it, and that UA levels correlated positively with hematocrit and hemoglobin levels. Conclusions: Hyperuricemia is an important public health problem among Tibetan men living at ultrahigh altitudes in Ganzi autonomous prefecture. The region urgently requires appropriate prevention and management efforts.
SMARCA4 encodes one of two mutually exclusive ATPase subunits in the BRG/BRM associated factor (BAF) complex that is recruited by transcription factors (TFs) to drive chromatin accessibility and transcriptional activation. SMARCA4 is among the most recurrently mutated genes in human cancer, including ∼30% of germinal center (GC)-derived Burkitt lymphomas. In mice, GC-specific Smarca4 haploinsufficiency cooperated with MYC over-expression to drive lymphomagenesis. Furthermore, monoallelic Smarca4 deletion drove GC hyperplasia with centroblast polarization via significantly increased rates of centrocyte recycling to the dark zone. Mechanistically, Smarca4 loss reduced the activity of TFs that are activated in centrocytes to drive GC-exit, including SPI1 (PU.1), IRF family, and NF-κB. Loss of activity for these factors phenocopied aberrant BCL6 activity within murine centrocytes and human Burkitt lymphoma cells. SMARCA4 therefore facilitates chromatin accessibility for TFs that shape centrocyte trajectories, and loss of fine-control of these programs biases toward centroblast cell-fate, GC hyperplasia and lymphoma.
Inclusion Criteria: Angiogram Cohort. Each study site will first identify adult patients (age 18 years or older) who presented to the study site 1) directly through the study site ED OR 2) as a transfer or referral patient from the ED of another institution OR 3) as a direct admission to the study site's Catheterization Laboratory by an ambulance service, who also met the following criteria: 1. Underwent coronary angiography during the index presentation for suspected ischemic symptoms (including but not limited to CP and/or SOB AND 2. Had a VPR ECG recorded during the index presentation prior to the angiogram AND 3. Had sufficient troponins to rule in or rule out acute myocardial injury, per the study site's institutional protocol. From this Angiogram Cohort, those who had TIMI-2 or greater flow will be identified for several research questions.
Portable device that monitors the 24-hour IOP pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals via an antenna around the orbital cavity to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization.
Colloid aliquots of 200 ml 6% hydroxy ethyl starch 130/ 0.4(Voluven) will be administered within 10 minutes and CVP response will be recorded. If CVP failed to rise sustainably for more than 2 mmHg for 20 minutes, the aliquot will be repeated.
FIELD: medicine, neurology, biochemistry. SUBSTANCE: invention proposes the use of glycoseaminoglycans extracted from the human placenta as an active component of an agent for treatment of patients with neurological diseases. The agent shows high therapeutic effectiveness, it does not induce toxic effect since exhibits homology with respect to human body tissues. Invention can be used in pharmacology for development of new medicinal preparations. EFFECT: enhanced effectiveness of agent. 10 tbl, 2 ex
The invention relates to activation of apoptin-induced apoptosis by different cell-transforming agents in normal and/or cancer-prone cells. Apoptin or also called VP3 is a viral protein derived from the Chicken anemia virus. Also the inven-tion relates to preventive anti-tumor ther-apies of normal and/or cancer-prone cells.  Treatment of normal and/or cancer-prone cells with tumor-inducing agents will ac-tivate apoptin-induced apoptosis, resulting in the elimination of potential tumor cells.  Also the invention relates to diagnosis of cancer agents. Agents with tumor activity can be examined by expressing them in nor-mal cells and analyzing their capability of enabling apoptin-induced apoptosis.
Pain subjects with radicular pain receiving gabapentin. Medication treatment groups will titrate up to the standard clinical treatment dosage for one week and maintain that dosage for 1.5 weeks.
The invention relates to a cyclopeptide nanotube medicinal composition and application thereof. The medicinal composition consists of a cyclopeptide nanotube and medicaments. The cyclopeptide nanotube has a vander Waals inside diameter of 0.75 to 1.3nm and a length of 10 to 100nm. A basic unit of the cyclopeptide nanotube is cyclopeptide which is formed by cyclizing 8, 10 and 12 amino acids. The diameter of the medicament molecule is smaller than the vander Waals inside diameter of the cyclopeptide nanotube. The invention also provides application of the cyclopeptide nanotube medicinal composition. The cyclopeptide nanotube medicinal composition uses the cyclopeptide nanotube as a transmembrane artificial nano channel, so that micromolecular medicaments enter cells in a mode of passive diffusion. The invention discovers the new medical use of the cyclopeptide nanotube medicinal composition. The medicaments rapidly enter the cells at a high concentration for improving the cytotoxicity thereof. Due to the synergistic effect of the medicaments with the cyclopeptide nanotube, the cyclopeptide nanotube medicinal composition has application potential in the oncotherapy, bacteria resistance, virus resistance, and other pathogen infection aspects.